Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

JAMA Network

Phase II data of frontline Ibrutinib and Venetoclax in 80 higher risk and older CLL patients. Patients had either del(17p) (18%), TP53-mutation (14%), unmutated

  • Phase II data of frontline Ibrutinib and Venetoclax in 80 higher risk and older CLL patients. Patients had either del(17p) (18%), TP53-mutation (14%), unmutated IGVH, or age>65. 75% achieved MRD negativity in the marrow and estimated 3 year PFS was 93%.